ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG CỦA BỆNH NHÂN LUPUS BAN ĐỎ HỆ THỐNG CÓ RỐI LOẠN LIPID MÁU

Abstract

Objectives: The study aims to determine the rate of dyslipidemia and describes the clinical and laboratory characteristics of patients with systemic lupus erythematosus with dyslipidemia. Subjects and methods: Cross-sectional descriptive study on 72 patients diagnosed with systemic lupus erythematosus according to SLICC 2012 criteria who were treated at the center of Allergology and Clinical Immunology, Bach Mai hospital from June 2021 to October 2022. Result: 69,44% of patients had dyslipidemia, in which the proportion of patients with increased cholesterol was 25%, increased triglycerides was 47,22%, increased LDL-C was 13,89% and decreased HDL-C was 41,67%. Concentrated mainly in the childbearing age; the female/male ratio was 7:1; the mean age was 36,11 ± 13,15 years old. The case group had a higher index of disease activity than the control group (12.39 ± 7.03 compared with 10.13 ± 5.57), the positive rate for antinuclear antibody (ANA), and anti-dsDNA double-stranded antibody  (dsDNA) of the case group was higher than that of the control group. In addition, the case group had C3, C4, and serum albumin was lower than the control group and 24-Hour Urine Protein was higher. A positive anti-dsDNA double-stranded antibody increases the risk of dyslipidemia by 10,2-fold. Conclusion: The rate of dyslipidemia in patients with systemic lupus erythematosus was high, there was a relationship between dyslipidemia and anti-dsDNA double-stranded antibodies.